# Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

> **NCT06865677** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 2 (actual)

## Conditions studied

- Recurrent Platinum Resistant Epithelial Ovarian Carcinoma
- Recurrent Epithelial Endometrial Carcinoma
- Recurrent Epithelial Cervical Carcinoma

## Interventions

- **DRUG:** Sacituzumab Govitecan
- **DIAGNOSTIC_TEST:** EKG
- **DIAGNOSTIC_TEST:** Brain MRI
- **DIAGNOSTIC_TEST:** CT scans
- **PROCEDURE:** Tumor biopsy
- **DRUG:** Loperamide
- **DRUG:** Octreotide
- **DRUG:** Diphenoxylate/Atropine
- **DRUG:** Antiemetics

## Key facts

- **NCT ID:** NCT06865677
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-06-09
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06865677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06865677, "Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06865677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*